Topline Presentation Points
- CARs in mantle cell lymphoma (MCL)
- ZUMA 2 Brex-Cel
- 67% CR and 27% PR
- Activity Similar Across All Risk Groups with MCL (Wang M, et al. N Engl J Med. 2020;382:1331–42; Wang et al ASH 2020.)
-
- TRANSCEND NHL 001 Lisocabtagene maraleucel (liso-cel)
- 66% CR and 19% PR(Palomba ASH 2020)
- CARs in indolent B-cell non-Hodgkin lymphoma (iB-NHL)
- ZUMA 5
- CR 80% and PR 14%
- The median time to first response was 1 mo (range, 0.8-3.1)
- Among the 25 patients with FL who initially had a PR, 13 (52%) subsequently converted to a CR after a median of 2.2 mo (range, 1.9-11.2)
(Jacobson ASH 2020)
- ZUMA-5: Retreatment
- ORR 100%
- 12m est PFS 58%
- Similar safety profile
- Similar peak cytokines (Chavez EHA 2021)
- SCHOLAR 5
- Rr FL treatment options from patient chart records from 7 multi-national institutions
(Ghione EHA 2021)
- ELARA
- Tisa-cel in r/r FL
- CR 66% and PR 20.2%
- Median follow-up for efficacy 11 (4.3-19.7) months
- Probability for a responding patient to remain in response > 6 months was 79% (95% CI, 66-87) (Schuster ASCO 2021)
